ARCHIVES

Drugs and Targets: FDA extends Lymphoseek label to include mapping in solid tumors

This article is from The Cancer Letter archive.

Vol. 40 No. 41 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts

June 14, 2013

DCT Adopts New Unsolicited Contract Review Procedures

May 21, 1976

ACS Clinical Awards Available For 1996

March 31, 1995

Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer

December 27, 2002

NCI Cooperative Group, Cancer Center Trials Listed

November 28, 2008

In Brief: NCI’s John Czajkowski Takes Executive Dean Position At Harvard Medical School

February 21, 2014